News CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:09 2026-10-02 EDT			5-day change	1st Jan Change
9.930 ^HKD	-1.39%		+6.43%	+17.79%

10-02	Major drugmakers turn to China for licensing deals	RE
10-01	CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study	MT

All News

Mentions Relevance

10-01	CSPC Reports Blood Sugar Reduction in Phase III Diabetes Study	MT
09-30	CSPC Pharmaceutical Group Limited Presents Results of Phase III Clinical Study of Efmedaglutide Alfa Injection in Combination with Metformin in Chinese Adult Patients with Type 2 Diabetes Mellitus	CI
09-29	CSPC Pharma Gets US FDA Approval to Start Herpes Zoster Vaccine Trial	MT
09-29	CSPC Pharma Begins Phase 1b Trial of Weight Management Drug in China	MT
09-28	CSPC Pharma Gets China Nod for Tumor Drug Trial	MT
09-28	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For SYS6077 Injection In China	CI
09-24	CSPC Pharmaceutical Group Limited Initiates Phase III Clinical Trial Of Docetaxel For Injection (Albumin-Bound) For Treatment Of Advanced Breast Cancer In China	CI
09-24	CSPC Pharmaceutical Group Limited Announces Phase III Clinical Trial Of Becotatug In Combination With Osimertinib Achieves Positive Topline Results	CI
09-24	CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results	MT
09-24	CSPC Pharm Begins Phase III Breast Cancer Drug Trial	MT
09-21	US Considers Rules Allowing American Investment in Chinese Drugs	MT
09-16	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2069 Injection For Treatment Of Type 2 Diabetes Mellitus In Adult Patients At First Centre In China	CI
09-16	CSPC Pharma Begins Diabetes Drug Trial in China	MT
09-15	CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug	MT
09-15	CSPC Pharmaceutical says SYS6010 granted breakthrough therapy designation by NMPA	RE
09-15	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 By NMPA In China For Treatment Of Actionable Genomic Alteration-Negative Non-Squamous Non-Small Cell Lung Cancer	CI
09-14	CSPC Pharmaceutical Group Limited Presents Phase I/II Clinical Trial Data Of SYS6010 In Combination With Enlonstobart For Treatment Of Advanced NSCLC At 2026 World Conference On Lung Cancer	CI
09-09	CSPC Pharma's SYH9087 Injection Gets China Nod for Parkinson's Disease Trial	MT
09-09	CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug	MT
09-09	CSPC Pharmaceutical Group Limited Announces Dopamine Receptor Agonist Rotigotine Long-Acting Injection (SYH9087 Injection)	CI
09-09	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For Goserelin Sustained-Release Injection (SYH9102 Injection)	CI
09-08	CSPC Pharmaceutical Group Limited SYH2083 Eye Drops Obtain Clinical Trial Approval In China	CI
09-08	CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials	MT
09-07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of SYH2085 Tablets for Treatment of Uncomplicated Influenza in Adults in China	CI
09-07	CSPC Pharma Begins Phase II Study of Influenza Drug in China	MT